Compliance with antipsychotic treatment

Objective: Despite the demonstrated efficacy of antipsychotics the relapse rate among patients with schizophrenia remains high. One major reason for this is non‐compliance. In this article we review different factors influencing compliance and discuss possibilities to enhance compliance among schizo...

Full description

Saved in:
Bibliographic Details
Published inActa psychiatrica Scandinavica Vol. 102; no. s407; pp. 83 - 86
Main Authors Oehl, M., Hummer, M., Fleischhacker, W. W.
Format Journal Article
LanguageEnglish
Published Copenhagen Munksgaard International Publishers 01.01.2000
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objective: Despite the demonstrated efficacy of antipsychotics the relapse rate among patients with schizophrenia remains high. One major reason for this is non‐compliance. In this article we review different factors influencing compliance and discuss possibilities to enhance compliance among schizophrenic patients. Method: This review is based on a systematic literature search in Medline. Results: We summarize the four main factors (patient‐, environment‐, physician‐ and treatment‐related) that influence compliance and discuss possible measures to enhance compliance. Next to many other variables discussed in more detail, it is crucial to ensure a positive doctor–patient relationship and to provide sufficient information about the benefit/risk ratio of the medication as well as about the illness itself to build up and sustain compliance. Significant others should be included into the therapeutic alliance whenever possible. Conclusion: Despite many published reports on compliance, it remains to be a problem of eminent clinical relevance. Clinicians must not underestimate it in order to optimize the treatment of patients with schizophrenia.
Bibliography:ark:/67375/WNG-NNJZXN2M-8
istex:BD272920F5219E7ADDF8D6631BCFD381EE23F614
ArticleID:ACPS016
This paper was read in preliminary version at the 1st International Zurich Conference on Clinical and Social Psychiatry, Zurich, 9–12 September 1999. The conference and this publication were sponsored by Eli Lilly Suisse.
ISSN:0001-690X
0065-1591
1600-0447
DOI:10.1034/j.1600-0447.2000.00016.x